Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

250.68
+6.142.51%
Post-market: 250.680.00000.00%16:40 EDT
Volume:1.22M
Turnover:305.49M
Market Cap:16.27B
PE:17.14
High:252.72
Open:241.39
Low:241.39
Close:244.54
52wk High:266.38
52wk Low:123.88
Shares:64.91M
Float Shares:62.69M
Volume Ratio:0.59
T/O Rate:1.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.39
PE(LYR):-42.92

Loading ...

Jazz Pharmaceuticals' Actio Acquisition 'Makes Sense,' Has Good Synergy, RBC Says

MT Newswires Live
·
Aug 11

Jazz Pharmaceuticals price target raised to $283 from $280 at Morgan Stanley

TIPRANKS
·
Aug 11

Wells Fargo Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Aug 11

Jazz Pharmaceuticals Buys Actio Biosciences for at Least $820 Million

MT Newswires Live
·
Aug 10

Jazz Bets on Epilepsy Treatment with up to $1.32 Billion Deal for Actio

Reuters
·
Aug 10

Jazz Pharmaceuticals - to Buy Actio Biosciences for $820 Mln Upfront, up to $500 Mln Contingent

THOMSON REUTERS
·
Aug 10

Jazz Pharmaceuticals - Actio Biosciences to Spin Out New Private Entity; Jazz to Receive Minority Stake

THOMSON REUTERS
·
Aug 10

Jazz Pharmaceuticals - Deal Expected to Close by Q4 2026, Subject to Conditions

THOMSON REUTERS
·
Aug 10

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

THOMSON REUTERS
·
Aug 10

Jazz Pharmaceuticals - to Fund Deal with Cash on Hand and Existing Financing Facilities

THOMSON REUTERS
·
Aug 10

Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 06

UBS Adjusts Jazz Pharmaceuticals Price Target to $315 From $307, Maintains Buy Rating

MT Newswires Live
·
Aug 05

Jazz Pharmaceuticals price target raised to $300 from $290 at Canaccord

TIPRANKS
·
Aug 05

Jazz Pharmaceuticals (JAZZ) Stock Climbs As Raised Guidance Backs Oncology Push

Simply Wall St.
·
Aug 05

Jazz Pharmaceuticals Delivers Strong Q2, Xywav Drives Higher Guidance, Morgan Stanley Says

MT Newswires Live
·
Aug 04

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results

Benzinga Earnings
·
Aug 04

Jazz Pharmaceuticals is Maintained at Outperform by Baird

Dow Jones
·
Aug 04

Jazz Pharmaceuticals price target raised to $270 from $260 at Barclays

TIPRANKS
·
Aug 04

Morgan Stanley Adjusts PT on Jazz Pharmaceuticals to $280 From $245, Maintains Overweight Rating

MT Newswires Live
·
Aug 04

Pharma Mar Says Jazz Pharmaceuticals to Seek FDA Withdrawal of Zepzelca Second-Line Use

Reuters
·
Aug 04